Global Immuno-Oncology Market Overview:
Global Immuno-Oncology Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2026-2035, Considering the Base Year As 2025.
Global Immuno-Oncology Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Immuno-Oncology involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Immuno-Oncology Market:
The Immuno-Oncology Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Immuno-Oncology Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Immuno-Oncology Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Immuno-Oncology market has been segmented into:
Lung Cancer
Melanoma
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
By Application, Immuno-Oncology market has been segmented into:
Checkpoint Inhibitors
Adoptive Cell Therapy
Cancer Vaccines
Oncolytic Viruses
Targeted Therapies
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Immuno-Oncology market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Immuno-Oncology market.
Top Key Players Covered in Immuno-Oncology market are:
Incyte
Bristol Myers Squibb
Gilead Sciences
Roche
Seagen
Merck Co.
Amgen
EMD Serono
AstraZeneca
AbbVie
Pfizer
Celgene
Ipsen
Novartis
BeiGene
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Immuno-Oncology Market Type
4.1 Immuno-Oncology Market Snapshot and Growth Engine
4.2 Immuno-Oncology Market Overview
4.3 Lung Cancer
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Lung Cancer: Geographic Segmentation Analysis
4.4 Melanoma
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Melanoma: Geographic Segmentation Analysis
4.5 Breast Cancer
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Breast Cancer: Geographic Segmentation Analysis
4.6 Colorectal Cancer
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.6.3 Colorectal Cancer: Geographic Segmentation Analysis
4.7 Leukemia
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.7.3 Leukemia: Geographic Segmentation Analysis
4.8 Lymphoma
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.8.3 Lymphoma: Geographic Segmentation Analysis
Chapter 5: Immuno-Oncology Market Application
5.1 Immuno-Oncology Market Snapshot and Growth Engine
5.2 Immuno-Oncology Market Overview
5.3 Checkpoint Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Checkpoint Inhibitors: Geographic Segmentation Analysis
5.4 Adoptive Cell Therapy
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Adoptive Cell Therapy: Geographic Segmentation Analysis
5.5 Cancer Vaccines
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Cancer Vaccines: Geographic Segmentation Analysis
5.6 Oncolytic Viruses
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Oncolytic Viruses: Geographic Segmentation Analysis
5.7 Targeted Therapies
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.7.3 Targeted Therapies: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Immuno-Oncology Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 INCYTE
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 BRISTOL MYERS SQUIBB
6.4 GILEAD SCIENCES
6.5 ROCHE
6.6 SEAGEN
6.7 MERCK CO.
6.8 AMGEN
6.9 EMD SERONO
6.10 ASTRAZENECA
6.11 ABBVIE
6.12 PFIZER
6.13 CELGENE
6.14 IPSEN
6.15 NOVARTIS
6.16 BEIGENE
Chapter 7: Global Immuno-Oncology Market By Region
7.1 Overview
7.2. North America Immuno-Oncology Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Lung Cancer
7.2.2.2 Melanoma
7.2.2.3 Breast Cancer
7.2.2.4 Colorectal Cancer
7.2.2.5 Leukemia
7.2.2.6 Lymphoma
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Checkpoint Inhibitors
7.2.3.2 Adoptive Cell Therapy
7.2.3.3 Cancer Vaccines
7.2.3.4 Oncolytic Viruses
7.2.3.5 Targeted Therapies
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Immuno-Oncology Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Lung Cancer
7.3.2.2 Melanoma
7.3.2.3 Breast Cancer
7.3.2.4 Colorectal Cancer
7.3.2.5 Leukemia
7.3.2.6 Lymphoma
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Checkpoint Inhibitors
7.3.3.2 Adoptive Cell Therapy
7.3.3.3 Cancer Vaccines
7.3.3.4 Oncolytic Viruses
7.3.3.5 Targeted Therapies
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Immuno-Oncology Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Lung Cancer
7.4.2.2 Melanoma
7.4.2.3 Breast Cancer
7.4.2.4 Colorectal Cancer
7.4.2.5 Leukemia
7.4.2.6 Lymphoma
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Checkpoint Inhibitors
7.4.3.2 Adoptive Cell Therapy
7.4.3.3 Cancer Vaccines
7.4.3.4 Oncolytic Viruses
7.4.3.5 Targeted Therapies
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Immuno-Oncology Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Lung Cancer
7.5.2.2 Melanoma
7.5.2.3 Breast Cancer
7.5.2.4 Colorectal Cancer
7.5.2.5 Leukemia
7.5.2.6 Lymphoma
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Checkpoint Inhibitors
7.5.3.2 Adoptive Cell Therapy
7.5.3.3 Cancer Vaccines
7.5.3.4 Oncolytic Viruses
7.5.3.5 Targeted Therapies
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Immuno-Oncology Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Lung Cancer
7.6.2.2 Melanoma
7.6.2.3 Breast Cancer
7.6.2.4 Colorectal Cancer
7.6.2.5 Leukemia
7.6.2.6 Lymphoma
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Checkpoint Inhibitors
7.6.3.2 Adoptive Cell Therapy
7.6.3.3 Cancer Vaccines
7.6.3.4 Oncolytic Viruses
7.6.3.5 Targeted Therapies
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Immuno-Oncology Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Lung Cancer
7.7.2.2 Melanoma
7.7.2.3 Breast Cancer
7.7.2.4 Colorectal Cancer
7.7.2.5 Leukemia
7.7.2.6 Lymphoma
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Checkpoint Inhibitors
7.7.3.2 Adoptive Cell Therapy
7.7.3.3 Cancer Vaccines
7.7.3.4 Oncolytic Viruses
7.7.3.5 Targeted Therapies
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Immuno-Oncology Scope:
|
Report Data
|
Immuno-Oncology Market
|
|
Immuno-Oncology Market Size in 2025
|
USD XX million
|
|
Immuno-Oncology CAGR 2025 - 2032
|
XX%
|
|
Immuno-Oncology Base Year
|
2024
|
|
Immuno-Oncology Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Incyte, Bristol Myers Squibb, Gilead Sciences, Roche, Seagen, Merck Co., Amgen, EMD Serono, AstraZeneca, AbbVie, Pfizer, Celgene, Ipsen, Novartis, BeiGene.
|
|
Key Segments
|
By Type
Lung Cancer
Melanoma
Breast Cancer
Colorectal Cancer
Leukemia
Lymphoma
By Applications
Checkpoint Inhibitors
Adoptive Cell Therapy
Cancer Vaccines
Oncolytic Viruses
Targeted Therapies
|
